drugset / Trial / NCT00005776

Inhaled Nitric Oxide Study for Respiratory Failure in Newborns

NCT00005776 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Respiratory failure in term newborns is associated with increased rates of death and long-term neurodevelopmental problems. This large international multicenter trial randomized newborns who had failed to respond to intensive care, including high levels of ventilator support, to receive either inhaled nitric oxide (iNO) or 100 percent oxygen to test whether iNO would decrease their risk of dying or requiring temporary lung bypass. Infants were followed during their initial hospitalization; their outcome was assessed at 18 to 24 mos of age.

Timeline

Start
1995-10
Primary completion
1996-05
Completion
1998-05

Outcome

Met primary endpoint

Stopped: “Results showed statistically significant benefit in the experimental group”

paper percent of the control group and 46 percent of the nitric oxide group died within 120 days or were treated with extracorporeal membrane oxygenation (P=0.006). PMID 9036320 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitric Oxide Other / unclassified 20 ppm Inhaled
Subject Nitric Oxide Other / unclassified 80 ppm Inhaled